Cargando…
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity
Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac complications including left ventricular dysfunction a...
Autores principales: | Diwadkar, Sachin, Patel, Aarti A., Fradley, Michael G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749759/ https://www.ncbi.nlm.nih.gov/pubmed/26942019 http://dx.doi.org/10.1155/2016/3456287 |
Ejemplares similares
-
Complete heart block and multisystem sarcoidosis: myocardial inflammation and scar imaging to guide diagnosis and management
por: Oji, Onyedikachi, et al.
Publicado: (2022) -
Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011) -
Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma
por: Paterek, Aleksandra, et al.
Publicado: (2023) -
Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
por: Meseeha, Marcelle G., et al.
Publicado: (2015) -
Complete heart block in COVID-19 without prior cardiac disease
por: Kavya, NP, et al.
Publicado: (2022)